leucovorin
Feb 23, 2024
Ipsen’s Onivyde Combo Ends a Decade-Long Dry Spell in Newly Diagnosed Pancreatic Cancer
It marks the awaited green light for Ipsen following its acquisition of Onivyde in 2017. The FDA has given its nod to the supplemental new drug application for Onivyde (irinotecan liposome injection) in combination with oxaliplatin, fluorouracil, and leucovorin (NALIRIFOX) as a primary treatment for adults with met...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
